As Dr. Sharon Fekrat and Dr. Dilraj S. Grewal told Reuters Health by email, "The changes we found in the small blood vessels in the retina and in the choroid may allow us to non-invasively assist in the diagnosis of PD by serving as an easily available screening tool."
"While more research is required on this technology," they added, "such a non-invasive and rapid biomarker could also detect disease progression and help evaluate the efficacy of new interventions being investigated in clinical trials. "
As reported online in JAMA Ophthalmology, Drs. Fekrat and Grewal of Duke University School of Medicine, Durham, North Carolina and colleagues studied 124 eyes of 69 patients with PD. A further 137 healthy participants (248 eyes) acted as controls.
Using optical coherence tomography (OCT) and OCT angiography, each eye of a patient with PD was compared with two eyes of an age- and sex-matched control participant. After exclusions, compared to controls, PD patients had reduced retinal vessel and perfusion densities, increased total choroidal area and choroid luminal area, and reduced choroidal vascularity index.
No differences in retinal structure were seen. However, say the investigators, "Subtle changes in the thickness of certain retinal layers and the choroid may be observed in specific individuals with PD and may be outside the limits of resolution of current imaging instrumentation."
The researchers further note that "because this is a cross-sectional study of individuals with varying degrees of PD severity, we were not able to identify the prognostic value of retinal imaging in PD." They call for further studies to "clarify whether these imaging findings may be useful as biomarkers for the onset of PD or the rapid deterioration from PD."
Commenting by email, Dr. Rajendra S. Apte of Washington University in St. Louis, Missouri, co-author of an accompanying editorial, told Reuters Health, "The retina as a window to neurodegenerative diseases of the brain such as Parkinson's and Alzheimer's disease offers exciting possibilities."
"Well-designed prospective studies that identify high risk patients that progress more rapidly, resilient populations, and potentially non-invasive method to gauge treatment response are highly desirable," Dr. Apte said.
SOURCE: https://bit.ly/38QMCaQ and https://bit.ly/34Vumw6 JAMA Ophthalmology, online December 23, 2020.
By David Douglas
Posted on
Previous Article
« Motor skill training improves pain, function in chronic low back pain Next Article
Two genes in prefrontal cortex implicated in post-traumatic stress disorder »
« Motor skill training improves pain, function in chronic low back pain Next Article
Two genes in prefrontal cortex implicated in post-traumatic stress disorder »
Related Articles
April 13, 2021
MS: EXCHANGE Trial Perspectives from Prof. Amit Bar-Or
October 27, 2021
Rehabilitation may work best 60-90 days after stroke
November 18, 2024
AI versus clinicians: who diagnoses MS faster and better?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com